Select your Market

Global
Global
CAREERS

Fiscal 2021: Record Growth and Higher Profitability

Group sales rise by 12.3% to € 19.7 billion; EBITDA pre up 17.3% to € 6.1 billion; EBITDA pre margin increases to 31.0%.

Overview and Outlook

Fiscal 2021

  • Group sales rise by 12.3% to € 19.7 billion; EBITDA pre up 17.3% to € 6.1 billion; EBITDA pre margin increases to 31.0%
  • Greater investments in high-growth businesses; net financial debt significantly lower
  • Earnings per share pre of € 8.72; proposed dividend rises by € 0.45 to all-time high of € 1.85

Forecast for 2022

  • Strong organic growth of net sales and EBITDA pre expected
  • All business sectors are forecast to contribute to the positive development; Life Science will remain the strongest growth engine of the Group
Belén Garijo - Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

Despite a difficult environment, we have stayed a reliable partner for patients, scientists and our customers – and were hence able to achieve a record result.

Belén Garijo

Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

ADDITIONAL INFORMATION

Financial Report
 

Downloads for the Media

Additional Downloads

Annual Reports Archive

Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more